Table 2.
Percentage of resistant Pseudomonas strains to relevant antibiotics from inpatient and outpatient departments (2008–2017).
| Tested Antibiotics | 2008–2012 | 2013–2017 | ||||
|---|---|---|---|---|---|---|
| Outpatients | Inpatients | Statistics a | Outpatients | Inpatients | Statistics a | |
| Amikacin | 18.3% (n = 52) | 22.1% (n = 116) | n.s. | 13.1% (n = 38) | 13.1% (n = 69) | n.s. |
| Gentamicin | 31.1% (n = 89) | 47.4% (n = 247) | p = 0.043 | 13.1% (n = 38) | 25.9% (n = 135) | p = 0.043 |
| Tobramycin | 28.6% (n = 82) | 44.2% (n = 231) | p = 0.038 | 18.2% (n = 52) | 22.7% (n = 119) | n.s. |
| Ciprofloxacin | 34.5% (n = 99) | 51.2% (n = 268) | p = 0.033 | 31.6% (n = 91) | 38.2% (n = 200) | n.s. |
| Levofloxacin | 39.4% (n = 113) | 54.8% (n = 286) | p = 0.033 | 33.9% (n = 98) | 41.5% (n = 217) | n.s. |
| Imipenem | 10.9% (n = 31) | 22.8% (n = 119) | p = 0.042 | 16.2% (n = 47) | 28.3% (n = 148) | p = 0.036 |
| Meropenem | 12.7% (n = 36) | 24.7% (n = 129) | p = 0.04 | 11.9% (n = 34) | 26.3% (n = 138) | p = 0.029 |
| Ceftazidime | 9.6% (n = 29) | 23.1% (n = 121) | p = 0.036 | 13.0% (n = 37) | 15.1% (n = 79) | n.s. |
| Cefepime | 14.9% (n = 43) | 23.3% (n = 122) | p = 0.045 | 9.5% (n = 27) | 12.1% (n = 63) | n.s. |
| Piperacillin/tazobactam | 11.2% (n = 32) | 21.9% (n = 115) | p = 0.045 | 16.9% (n = 48) | 18.4% (n = 96) | n.s. |
| Colistin | 0% (n = 2) | 0% (n = 3) | - | 0% (n = 10) | 0% (n = 12) | - |
a Comparison of resistance levels among isolates originating from outpatients and inpatients; Statistical analyses were performed using the Student’s t-test; p values < 0.05 were considered statistically significant, n.s.: Not significant.